“Good decisions come from experience, and experience comes from bad decisions … and paying attention.”
You’ve probably heard the first part of that before, but the “… and paying attention” is my addition and reflection upon reading Lynn Silver’s most recent commentary in the Springer Series Topics in Medicinal Chemistry, edited by Jed Fisher, Marvin Miller and Shahriar Mobashery. Entitled “The Antibiotic Future,” it is a discussion of the hurdles of antibiotic discovery and a summary of Lynn’s far-ranging & pithy insights. It’s not open access so you’ll have to download yourself, but here’s the link and the abstract:
Lynn is truly a master of this field and she has over the years written many instructive papers. Just below, I provide a list of some of my favorites from her published works. If you’re doing drug discovery and haven’t explored her writings, I strongly encourage you to take an afternoon to study them in detail. I especially recommend the 2011 paper in CMR:
Finally, and if you’re interested in non-antibiotic alternative approaches,Lynn's comments on this area may make you want to dig further. A good place to start would be with the 3 papers below -- collectively, they provide a good set of pro-con comments on the challenges of this strategy. The alternatives that seek to work in combination or as enhancers are going to be very tricky to develop and it's important to understand the issues:
In short, knowing what has come before is the only way that I know to avoid repeating past mistakes. If you're going to make a mistake, please make a new one ... it's much more productive! Many thanks to Lynn for sharing her insights via these publications.
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html
Upcoming meetings of interest to the AMR community: